Supernus Pharmaceuticals (NASDAQ:SUPN) Director Sells $315,132.82 in Stock

Key Points

• Supernus Pharmaceuticals Director Frederick M. Hudson sold 7,457 shares at an average price of $42.26, totaling approximately $315,132.82, which decreased his stake in the company by 13.87%.
• Supernus Pharmaceuticals' stock rose by 0.7% to $42.99, with an average trading volume of 682,108 shares compared to its usual volume of 638,685.
• Several analysts have recently upgraded Supernus Pharmaceuticals, including Cantor Fitzgerald, which raised its price target from $42.00 to $46.00 and assigned it an "overweight" rating.

Supernus Pharmaceuticals, Inc. (NASDAQ:SUPN - Get Free Report) Director Frederick M. Hudson sold 7,457 shares of the stock in a transaction dated Thursday, August 14th. The stock was sold at an average price of $42.26, for a total transaction of $315,132.82. Following the completion of the sale, the director directly owned 46,307 shares in the company, valued at approximately $1,956,933.82. This trade represents a 13.87% decrease in their position. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available at the SEC website.

Supernus Pharmaceuticals Trading Up 3.6%

SUPN traded up $1.56 on Friday, reaching $44.88. The company had a trading volume of 1,047,668 shares, compared to its average volume of 1,064,514. The company has a fifty day moving average of $35.41 and a 200-day moving average of $33.69. The company has a market capitalization of $2.52 billion, a P/E ratio of 39.03 and a beta of 0.74. Supernus Pharmaceuticals, Inc. has a one year low of $29.16 and a one year high of $45.01.

Hedge Funds Weigh In On Supernus Pharmaceuticals

Several large investors have recently made changes to their positions in SUPN. Rubric Capital Management LP bought a new position in shares of Supernus Pharmaceuticals during the 2nd quarter valued at about $21,908,000. Armistice Capital LLC boosted its position in shares of Supernus Pharmaceuticals by 7.4% during the 1st quarter. Armistice Capital LLC now owns 5,196,000 shares of the specialty pharmaceutical company's stock valued at $170,169,000 after purchasing an additional 360,000 shares in the last quarter. Sofinnova Investments Inc. boosted its holdings in shares of Supernus Pharmaceuticals by 53.5% in the second quarter. Sofinnova Investments Inc. now owns 799,253 shares of the specialty pharmaceutical company's stock worth $25,192,000 after buying an additional 278,575 shares during the period. Woodline Partners LP boosted its holdings in shares of Supernus Pharmaceuticals by 124.8% in the fourth quarter. Woodline Partners LP now owns 423,828 shares of the specialty pharmaceutical company's stock worth $15,326,000 after buying an additional 235,257 shares during the period. Finally, BNP Paribas Financial Markets boosted its holdings in shares of Supernus Pharmaceuticals by 248.0% in the fourth quarter. BNP Paribas Financial Markets now owns 292,629 shares of the specialty pharmaceutical company's stock worth $10,581,000 after buying an additional 208,552 shares during the period.

Wall Street Analyst Weigh In

A number of brokerages recently issued reports on SUPN. Zacks Research upgraded shares of Supernus Pharmaceuticals from a "strong sell" rating to a "hold" rating in a research report on Tuesday. Cantor Fitzgerald increased their target price on shares of Supernus Pharmaceuticals from $42.00 to $46.00 and gave the company an "overweight" rating in a research report on Wednesday, August 6th. Finally, Wall Street Zen upgraded shares of Supernus Pharmaceuticals from a "hold" rating to a "buy" rating in a research report on Saturday, August 2nd. Two equities research analysts have rated the stock with a Buy rating and two have issued a Hold rating to the company's stock. Based on data from MarketBeat.com, the company currently has a consensus rating of "Moderate Buy" and a consensus target price of $41.00.

Supernus Pharmaceuticals Company Profile

Supernus Pharmaceuticals, Inc, a biopharmaceutical company, focuses on the development and commercialization of products for the treatment of central nervous system (CNS) diseases in the United States. The company's commercial products are Trokendi XR, an extended release topiramate product indicated for the treatment of epilepsy, as well as for the prophylaxis of migraine headache; and Oxtellar XR, an extended release oxcarbazepine for the monotherapy treatment of partial onset seizures in adults and children between 6 to 17 years of age.